Research programme: type 2 diabetes therapy - MDRNA
Latest Information Update: 05 Aug 2008
At a glance
- Originator Nastech Pharmaceutical Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 09 Nov 2004 Preclinical trials in Type-2 diabetes mellitus in USA (Intranasal)